title: Hospital resources for urokinase/recombinant tissue-type plasminogen activator therapy for acute stroke in Beijing.
abstract: BACKGROUND
  We focus on the current resource level for UK/rt-PA therapy in hospitals in Beijing to design strategies for improving treatment for stroke patients.
  
  
  METHODS
  The data were collected through surveys of 124 grade II or higher hospitals in Bejing, which provide stroke treatment, from July to September 2006.
  
  
  RESULTS
  Of the surveyed hospitals, 50% and 92.6% were capable in providing intravenous UK/rt-PA treatment and head CT service, respectively. Eight (7.4%) hospitals have specialized stroke units and 106 (98.1%) hospitals have EDs. We found significant differences between hospitals that can provide UK/rt-PA therapy and the hospitals that cannot in the levels of specialists and clinical care capacity as follows: CT (100% vs 85.2%; P = 0.01), CTA (46.3% vs 22.2%; P = .014), MRI (66.7% vs 22.2%; P = .000), MRA (57.4% vs 20.4%; P = .000), DWI (48.1% vs 9.3%; P = .000), PWI (31.5% vs 5.6%; P = .001), DSA (63.0% vs 25.9%; P = .000), neurologists (100% vs 79.6%; P = .001), neurosurgeons (75.9% vs 44.4%; P = .002), carotid stenting (33.3% vs 5.6%; P = .000), stroke unit (14.8% vs 0%; P = .01), and acute stroke care system (31.5% vs 0%; P = .000).
  
  
  CONCLUSIONS
  The thrombolysis treatment facilities in Beijing are not sufficient. Hospitals in Beijing should organize stroke-related medical sources.
authors.affiliation: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China. yilong528@gmail.com
authors.forename: Yilong
authors.initials: Y
authors.lastname: Wang
authors.forename: Di
authors.initials: D
authors.lastname: Wu
authors.forename: Xingquan
authors.initials: X
authors.lastname: Zhao
authors.forename: Ruihua
authors.initials: R
authors.lastname: Ma
authors.forename: Xiangping
authors.initials: X
authors.lastname: Guo
authors.forename: Chunxue
authors.initials: C
authors.lastname: Wang
authors.forename: Liping
authors.initials: L
authors.lastname: Liu
authors.forename: Weijiang
authors.initials: W
authors.lastname: Zhao
authors.forename: Yongjun
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D002681:China; D004636:Emergency Service, Hospital / Q000706:statistics & numerical data*; D004638:Emergency Treatment; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D015276:Health Care Rationing / Q000706:statistics & numerical data; D019538:Health Care Surveys; D006295:Health Resources / Q000600:supply & distribution*; D006757:Hospital Units / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D040841:Resource Allocation / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*; D000078329:Workforce
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator